ENTA
Enanta Pharmaceuticals, Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 56 | -3 | 10.74M | $156.55M | +2 | −5 |
| Q1 2026 | 62 | -2 | 14.86M | $187.69M | +5 | −7 |
| Q4 2025 | 64 | +3 | 16.10M | $253.79M | +3 | — |
| Q3 2025 | 16 | +1 | 7.96M | $95.31M | +2 | −1 |
| Q2 2025 | 12 | 0 | 8.38M | $63.38M | — | — |
| Q1 2025 | 9 | -2 | 4.49M | $24.81M | — | −2 |
| Q4 2024 | 11 | -1 | 4.05M | $23.26M | — | −1 |
| Q3 2024 | 11 | +2 | 4.15M | $43.00M | +2 | — |
| Q2 2024 | 9 | — | 3.87M | $50.19M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Marshall Wace ✦ | 928.36K | — | $12.04M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Millennium Management ✦ | 683.14K | — | $8.86M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | D. E. Shaw & Co. ✦ | 534.18K | — | $6.93M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | D. E. Shaw & Co. ✦ | 534.18K | — | $6.93M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Renaissance Technologies ✦ | 510.90K | — | $6.63M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Citadel Advisors ✦ | 465.38K | — | $6.04M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Citadel Advisors ✦ | 465.38K | — | $6.04M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Geode Capital Management ✦ (passive) | 462.78K | — | $6.00M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Geode Capital Management ✦ (passive) | 462.78K | — | $6.00M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Two Sigma Investments ✦ | 184.56K | — | $2.39M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | AQR Capital Management ✦ | 60.01K | — | $778,265 | 0.0% | n/c | 1 | SEC ↗ |
| 12 | AQR Capital Management ✦ | 60.01K | — | $778,265 | 0.0% | n/c | 1 | SEC ↗ |
| 13 | Norges Bank ✦ (passive) | 40.70K | — | $527,879 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 131 holders, 26.72M shares, $290.62M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.